403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Gene Therapies For Cancer Treatment Market Projects USD 238.77 Billion At 39.94% CAGR By 2034
| Table | Scope | |
| Market Size in 2025 | USD 11.59 Billion | |
| Projected Market Size in 2034 | USD 238.77 Billion | |
| CAGR (2025 - 2034) | 39.94 | % |
| Leading Region | North America by 42% | |
| Market Segmentation | By Therapy Type/Modality, By Cancer Type/Indication, By Vector/Delivery Method, By Treatment Setting, By Distribution Channel, By Region | |
| Top Key Players | Immatics, Legend Biotech, Celyad Oncology, BioNTech, Editas Medicine, Astellas Pharma, Kite Pharma, Allogene Therapeutics, OncoImmune, Takeda, Sangamo Therapeutics, Beam Therapeutics, Charles River Laboratories |
What are the Major Growth Drivers in the Market?
Advances in genetic engineering and delivery systems are the major drivers in the gene therapies for cancer treatment market. These advancements are enhancing the safety and effectiveness of the treatment options. Additionally, growing acceptance of CAR-T therapies, R&D investments, combination therapies, growing patient awareness, and demand for personalized medicines
What are the Key Drifts in the Market?
The gene therapies for cancer treatment market has been expanding due to the growing funding to launch and enhance the use of various cancer gene therapies.
- In May 2025, to search for the efficacy of engineered CD4 and CD8 T cells for the treatment of advanced pancreatic cancer, a total of $500,000 grant was provided to the scientists of Fred Hutchinson Cancer Center by Alliance for Cancer Gene Therapy (ACGT) and the Mark Foundation for Cancer Research. In February 2025, the USC investigators developing a first-of-its-kind genetic therapy for glioblastoma, which is a severe form of brain cancer, were awarded a total of $6 million grant by the California Institute for Regenerative Medicine.
What is the Significant Challenge in the Market?
High treatment costs act as the major challenge in the gene therapies for cancer treatment market. This limits their adoption and acceptance rates by the hospitals as well as the patients. Moreover, complex manufacturing, severe side effects, limited infrastructure, and reimbursement challenges are other market limitations.
Become a valued research partner with us -Regional Analysis
Why did North America Dominate the Market in 2024?
In 2024, North America captured the biggest revenue share of 42% in the gene therapies for cancer treatment market, due to the presence of a robust R&D ecosystem. They were further supported by the healthcare investments, where the growing FDA approval enhanced these innovations. Advanced hospitals also increased their use, which contributed to the market growth.
What Made the Asia Pacific Grow Fastest in the Market in 2024?
Asia Pacific is expected to host the fastest-growing gene therapies
Get the latest insights on life science industry segmentation with our Annual Membership:Segmental Insights
By therapy type/modality analysis
Why Did the CAR-T Cell Therapy Segment Dominate in the Market in 2024?
By therapy type/modality, the CAR-T cell therapy segment led the gene therapies for cancer treatment market with approximately 35% share in 2024, due to its high efficacy. Moreover, they also offered target-specific action, which reduced the side effects. They also provided long-term immune surveillance against cancer.
By therapy type/modality, the oncolytic virus therapy segment is expected to show the highest growth in the market over the upcoming years, due to its dual action, which targets tumor cells and enhances immune responses. This is reducing the side effects and increasing their use in various cancer types. They are also being used in combination with other treatment options.
By cancer type/indication analysis
Which Cancer Type/Indication Type Segment Held the Dominating Share of the Market in 2024?
By cancer type/indication, the hematological cancers segment held the dominating share of approximately 42% of the gene therapies for cancer treatment market in 2024, driven by their specific target identification. They also provided high success rates, which increased their acceptance rates. Moreover, fast approvals increased their R&D.
By cancer type/indication, the melanoma & skin cancers segment is expected to show the fastest growth rate in the market during the upcoming years, due to high immunogenicity. Additionally, the proven success of these therapies is increasing their use with other potential treatment options.
By vector/delivery method analysis
What Made Lentiviral Vectors the Dominant Segment in the Market in 2024?
By vector/delivery method, the lentiviral vectors segment led the gene therapies for cancer treatment market with approximately 30% share in 2024, due to their durable and sustained therapeutic effects. They also provided high transduction efficiency. Furthermore, their large genetic payload capacity also increased their use for cancer treatment.
By vector/delivery method, the non-viral delivery segment is expected to show the highest growth in the market during the upcoming years, driven by its improved safety profile. They also showed minimized immunogenicity, which is increasing their combination with other therapeutic approaches, where their simple manufacturing is also enhancing their use.
By treatment setting analysis
How the Hospital/Oncology Centers Segment Dominated the Market in 2024?
By treatment setting, the hospital/oncology centers segment held the largest share of approximately 60% share of the gene therapies for cancer treatment market in 2024, as they offer complex treatment procedures. They also provided expert supervision, which increased the patient's trust. Moreover, they also offer post-treatment care, which has also increased the patient outcomes.
By treatment setting, the home/outpatient self-administered programs segment is expected to show the fastest growth rate in the market during the predicted time, as it provides patient convenience and comfort. The growing digital health integrations are also increasing their use, which helps in reducing the number of hospital visits and costs.
By distribution channel analysis
Why Did the Hospital Pharmacies/Infusion Centers Segment Dominate in the Market in 2024?
By distribution channel, the hospital pharmacies/infusion centers segment led the gene therapies for cancer treatment market with approximately 55% share in 2024, as they offer specialized storage and handling of the therapies. They comply with treatment protocol and are directly accessible to the patient, which increased their use.
By distribution channel, the direct-to-patient/home delivery segment is expected to show the highest growth in the market during the predicted time, as this enhances patient convenience. They also provide personalized therapy and remote monitoring, which is enhancing their acceptance rates.
Browse More Insights of Towards Healthcare:
The global gene editing cell line generation service market
The gene therapy clinical trials market
The gene editing therapeutics market
The global gene expression market
The global gene vector market
The global gene knockdown stable cell line service market
The worldwide gene therapy for sickle cell disease market
The global gene therapy cell culture media market
The gene synthesis market
The gene synthesis service market
Recent Developments in the Market
- In November 2025, the world's first humanised CAR-T therapy that is NexCAR19, for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphoma and B-cell Acute Lymphoblastic Leukaemia, was launched in India by ImmunoACT. In November 2025, a patent is intended to be granted for the use of Reqorsa® Gene Therapy in combination with PD-1 antibodies for cancer treatment by the European Patent Office (EPO) to Genprex, Inc.
Gene Therapies for Cancer Treatment Market Key Players List
- Celyad Oncology Immatics BioNTech Legend Biotech Kite Pharma Editas Medicine Astellas Pharma Oncolmmune Allogene Therapeutics Charles River Laboratories Takeda Beam Therapeutics Sangamo Therapeutics
Segments Covered in The Report
By Therapy Type/Modality
- CAR-T Cell Therapy Oncolytic Virus Therapy TCR (T-cell Receptor) Therapy Gene Editing/CRISPR-based Therapies RNA-based Gene Therapies (siRNA/mRNA) Other/Combination Approaches
By Cancer Type/Indication
- Hematological Cancers Melanoma & Skin Cancers Solid Tumors Prostate & Genitourinary Cancers Other Rare/Pediatric Cancers
By Vector/Delivery Method
- Lentiviral Vectors Non-viral Delivery Adenoviral/Adeno-Associated Viral (AAV) Vectors Retroviral Vectors Other/Hybrid Delivery Approaches
By Treatment Setting
- Hospital/Oncology Centers Home/Outpatient Self-administered Programs Specialty Cell & Gene Therapy Clinics Research & Clinical Trial Centers
By Distribution Channel
- Hospital Pharmacies/Infusion Centers Direct-to-Patient/Home Delivery Specialty Pharmacies/Biotech Distributors Other (Clinical Trial Supply Channels)
By Region
North America
- U.S. Canada Mexico Rest of North America
South America
- Brazil Argentina Rest of South America
Europe
- Western Europe
- Germany Italy France Netherlands Spain Portugal Belgium Ireland UK Iceland Switzerland Poland Rest of Western Europe
- Austria Russia & Belarus Türkiye Albania Rest of Eastern Europe
Asia Pacific
- China Taiwan India Japan Australia and New Zealand, ASEAN Countries (Singapore, Malaysia) South Korea Rest of APAC
MEA
- GCC Countries Saudi Arabia United Arab Emirates (UAE) Qatar Kuwait Oman Bahrain South Africa Egypt Rest of MEA
Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard:About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research You can place an order or ask any questions, please feel free to contact us at ...Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web:Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment